Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.87 USD | -0.84% | +5.32% | -21.65% |
May. 29 | Zentalis Pharmaceuticals Announces Appointment of Luke Walker, M.D., to Board of Directors | CI |
May. 24 | Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial | MT |
Business Summary
Number of employees: 124
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 20-06-30 | |
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 22-10-16 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Kyle Rasbach
IRC | Investor Relations Contact | - | Jan. 18 |
Kimberly Freeman
PRN | Corporate Officer/Principal | - | 23-07-31 |
- | - | ||
Andrea Paul
LAW | General Counsel | 43 | 22-07-31 |
Meena Rao
LAW | General Counsel | - | - |
Corporate Officer/Principal | 61 | 20-02-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Karan Takhar
BRD | Director/Board Member | 32 | 17-11-30 |
Jan Skvarka
BRD | Director/Board Member | 57 | 22-09-11 |
Enoch K. Kariuki
BRD | Director/Board Member | 42 | 21-02-08 |
David Johnson
CHM | Chairman | 59 | 20-01-08 |
Chief Executive Officer | 55 | 20-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 71,013,233 | 68,374,815 ( 96.28 %) | 0 | 96.28 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.65% | 844M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ZNTL Stock
- Company Zentalis Pharmaceuticals, Inc.